An interventional study of Oxytocin and Ergot in Postpartum Hemorrhage, sponsored by Samuel Lunenfeld Research Institute, Mount Sinai Hospital. Completed at 1 site in Canada. Open to female participants aged 14 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-09-24.
Sponsored by Samuel Lunenfeld Research Institute, Mount Sinai Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 34 studies in Postpartum Hemorrhage by Samuel Lunenfeld Research Institute, Mount Sinai Hospital — 5 open to participants now, 6 under way, none of them phase 3. Postpartum Hemorrhage · Samuel Lunenfeld Research Institute, Mount Sinai Hospital.
Among the 34 studies in Postpartum Hemorrhage by Samuel Lunenfeld Research Institute, Mount Sinai Hospital, this one is the 6th largest by enrollment of the 32 interventional ones that give a count, is one of 3 that started in 2013, is one of 32 with no phase, and was the 9th registered.
471 studies on the registry are indexed under Postpartum Hemorrhage; 76 are open to participants now.
Browse Postpartum Hemorrhage studies →5 of the 34 studies in Postpartum Hemorrhage by Samuel Lunenfeld Research Institute, Mount Sinai Hospital are open now, in 1 country. Recruiting first, the newest first:
Samuel Lunenfeld Research Institute, Mount Sinai Hospital · Sites in Canada
Ages 18–45 · Women only · Healthy volunteers
Samuel Lunenfeld Research Institute, Mount Sinai Hospital · Sites in Canada
Ages 18–40 · Women only · Healthy volunteers
Samuel Lunenfeld Research Institute, Mount Sinai Hospital · Sites in Canada
Ages 18–50 · Women only · Healthy volunteers
Samuel Lunenfeld Research Institute, Mount Sinai Hospital · Sites in Canada
Ages 18–45 · Women only · Healthy volunteers
Samuel Lunenfeld Research Institute, Mount Sinai Hospital · Sites in Canada
Ages 18–50 · Women only · Healthy volunteers
By country, each count listing its studies:
Of the 41 Postpartum Hemorrhage studies recruiting now, 21 (51%) set no upper age limit and 20 (49%) stop at 75 or younger; 6 take children under 18; 20 take healthy volunteers.
This study: 14 Years to 55 Years · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
34 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 3 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 105 is below the median of 146 across 361 interventional studies indexed under Postpartum Hemorrhage.
Median enrollment 40 across the 32 interventional studies, 102 across the 2 observational. Of the 28 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Samuel Lunenfeld Research Institute, Mount Sinai Hospital is the lead sponsor of 138 studies on the registry; 17 are open to participants now.
5 of the studies in Postpartum Hemorrhage by Samuel Lunenfeld Research Institute, Mount Sinai Hospital that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05290129Samuel Lunenfeld Research Institute, Mount Sinai HospitalOxytocin Maintenance Infusion in Labouring Women Undergoing Cesarean Delivery: an Up-down Sequential Allocation Study | 2026-12 |
| NCT06285409Samuel Lunenfeld Research Institute, Mount Sinai HospitalComparing the Dose-response Profiles of Uterotonics After Initial Carbetocin Administration - an Ex-vivo Study in Desensitized Human Myometrium | 2026-12 |
| NCT06333340Samuel Lunenfeld Research Institute, Mount Sinai HospitalComparative Efficacy of Carbetocin and Oxytocin in Parturients at Risk of Atonic Postpartum Hemorrhage Undergoing Elective Cesarean Delivery | 2026-12 |
| NCT07187544Samuel Lunenfeld Research Institute, Mount Sinai HospitalEffect of Co-administration of Carbetocin and Calcium Chloride on Uterine Tone in Patients Undergoing Elective Cesarean Delivery | 2026-12 |
| NCT06930391Samuel Lunenfeld Research Institute, Mount Sinai HospitalEffect of Extracellular Calcium on Carbetocin Mediated Contractility in Human Myometrium | 2027-06 |
Add all 5 to your calendar (.ics) → With an account.
Among the 34 studies in Postpartum Hemorrhage by Samuel Lunenfeld Research Institute, Mount Sinai Hospital, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Patients having Cesarean section after they have been in labor for many hours bleed much more, in average twice as much, as compared with patients having an elective Cesarean section. The investigators believe a simple change in practice might contribute to reduce this bleeding. This study will involve the use of oxytocin (also known as syntocinon), ergonovine (also known as ergot) and carboprost (also known as hemabate). Oxytocin is routinely used to help contract the uterus and keep it contracted after the delivery of the baby and placenta, so as to reduce the amount of blood loss. Ergonovine is also given through the intravenous line, while carboprost is given as an injection in the muscle. Although they are not routinely given in every case, these are very frequently given as rescue medications to patients who fail to respond appropriately to oxytocin. This study is designed to determine if ergonovine or carboprost given in association with oxytocin, in a preventive way, after delivery of the baby and placenta, can reduce the amount of blood loss during Cesarean sections following a trial of labour.
The objective of the investigators study is to compare the efficacy of intravenous ergonovine and intramuscular carboprost, when administered with oxytocin infusion, prophylactically to decrease blood loss at Cesarean section for labor arrest. Desensitization of the oxytocin receptors has been recently demonstrated in cultured human myometrial cells after continuous and prolonged exposure to oxytocin in-vitro. This could be also the reason for a greater risk of uterine atony and postpartum hemorrhage (PPH) seen in women requiring induction and augmentation of labor. Therefore, addition of a different uterotonic agent, involving a different mechanism of action, to oxytocin infusion is likely to be beneficial, especially in women undergoing CS following failure to progress in labor, who are at a greater risk for PPH.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Oxytocin 5IU IV bolus, followed by an infusion of oxytocin 20IU/L, running at at rate of 40mIU/min for 8 hours
Drug: Oxytocin
Oxytocin 5IU IV bolus + Ergot 0.25mg IV, followed by an infusion of oxytocin 20IU/L, running at at rate of 40mIU/min for 8 hours
Drug: Oxytocin · Drug: Ergot
Oxytocin 5IU IV bolus + Carboprost 0.25mg IM, followed by an infusion of oxytocin 20IU/L, running at at rate of 40mIU/min for 8 hours
Drug: Oxytocin · Drug: Carboprost
Oxytocin 5IU IV bolus, followed by an infusion of oxytocin 20IU/L, running at at rate of 40mIU/min for 8 hours
Also known as: syntocinon
Ergot 0.25mg IV
Also known as: ergonovine maleate
Carboprost 0.25mg IM
Also known as: Hemabate®
Need for additional uterotonics intraoperatively
Need for additional uterotonics intraoperatively if requested by the surgeon, YES or NO
Time frame: 1 hour
Effectiveness of uterine contraction
Adequate/inadequate uterine tone at 3,5 \& 10 min
Time frame: 10 min
Need for blood transfusion
Any blood products administered
Time frame: 24 hours
Vital signs
In the OR, heart rate, blood pressure, and oxygen saturation will be measured and looked at for abnormalities
Time frame: 2 hours
Side effects
The presence of nausea, vomiting,other dysrhythmias, chest pain, headache, bronchospasm and any others will be recorded.
Time frame: 24 hours
Estimated blood loss
calculated blood loss = EBV (Pre-op Htc-Post-op Htc) EBV (estimated blood volume, mL)=patient's weight in kg x 85
Time frame: 48 hours
Need for additional uterotonics or interventions post-operatively
Need for additional uterotonics or interventions post-operatively up to 24 hours post-partum
Time frame: 24 hours
Ran from Jun 2013 to primary completion in Jul 2019, 73 months.
Of 112 non-industry interventional studies with no phase under Postpartum Hemorrhage, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 28. This study's 73 months is above that.
Counting every sponsor, half of 119 studies reached it within 16 months; a quarter within 7 and three quarters within 26.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Ergonovine · Carboprost
Samuel Lunenfeld Research Institute, Mount Sinai Hospital →